Tigress Financial reiterates a Buy rating on Boeing (BA) and initiates a 12-month price target of $275 on the shares. Boeing’s record $600B backlog, representing more than 5,900 aircraft orders, provides multi-year revenue visibility, says the analyst, who notes that the firm’s price target represents a potential return of over 25% from current levels. Claim 70% Off TipRanks This Holiday Season Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Core Viewpoint - Atlassian (TEAM) has shown a significant price increase of 10.1% over the past four weeks, with a mean price target of $233.15 indicating a potential upside of 44.8% from the current price of $161.07 [1]. Price Targets - The average price target consists of 26 estimates, ranging from a low of $178.00 to a high of $320.00, with a standard deviation of $36.51, indicating variability among analysts [2]. - The lowest estimate suggests a 10.5% increase, while the highest points to a 98.7% upside, highlighting the range of analyst expectations [2]. Analyst Consensus and Earnings Estimates - Analysts are optimistic about TEAM's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown an 18.4% increase over the last 30 days with no negative revisions [11][12]. - The Zacks Consensus Estimate for the current year has increased, reflecting a strong agreement among analysts regarding the company's earnings potential [12][13]. Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be prudent due to concerns about analysts' biases and the accuracy of their predictions [3][7][10]. - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]. Conclusion on Investment Potential - Despite the skepticism surrounding price targets, the direction indicated by the consensus and the positive earnings revisions suggest a potential upside for TEAM [14].

Core Viewpoint - Assurant, Inc. is a global provider of risk management solutions, focusing on housing and lifestyle markets, and competes with other firms in the insurance and risk management sector [1] Group 1: Analyst Ratings and Price Targets - Piper Sandler maintains an "Overweight" rating for Assurant, raising its price target from $252 to $264, indicating confidence in the company's future performance [2][6] - Assurant has received an average recommendation of "Moderate Buy" from ten research firms, with eight analysts recommending buying the stock and two suggesting holding it, reflecting general optimism [3][6] - Truist Financial set a price objective of $255 for Assurant, while UBS Group raised their price target from $255 to $257, maintaining a "buy" rating [4] Group 2: Stock Performance and Market Capitalization - Assurant's stock is currently priced at $238.03, with a slight increase of 0.42%, and has fluctuated between $234.66 and $240.58 today [5][6] - The stock's year-high is $240.58, and the lowest price over the past year was $174.97, indicating significant price movement [5] - Assurant's market capitalization is approximately $11.92 billion, with a trading volume of 305,710 shares today [5][6]

Core Insights - Carnival Corporation & plc is a significant player in the leisure travel industry, operating a large fleet of cruise ships under various brand names, and competes with major cruise lines like Royal Caribbean and Norwegian Cruise Line [1] Price Target Trends - The consensus price target for Carnival's stock has increased from $33.89 to $36.64 over the past year, indicating growing optimism among analysts regarding the company's future prospects [2][6] - Analyst Stuart Gordon from Berenberg Bank has set a more conservative price target of $23, reflecting cautious optimism ahead of the fourth-quarter earnings report [3][6] Upcoming Earnings Report - Carnival is expected to announce its fourth-quarter earnings results soon, which is highly anticipated by investors, with analysts revising their forecasts for higher earnings [3][4] - The upcoming earnings report is seen as a pivotal moment for Carnival and the cruise industry, with strong bookings and favorable pricing contributing to an optimistic outlook, despite ongoing cost pressures [4][6] - Investors are closely monitoring the earnings report, as it could significantly influence the short-term trajectory of cruise stocks [4][5]

Allot Communications (ALLT) closed the last trading session at $8.71, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.5 indicates a 55% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $1.32. While the lowest estimate of $12.50 indicates a 43.5% increase from the current price level, the most optimistic analyst ...

Core Viewpoint - Morgan Stanley has set a price target of $331 for JPMorgan Chase & Co., indicating a potential increase of about 10.16% from its current trading price of $300.47, despite recent challenges faced by the company [2][5]. Financial Performance - JPMorgan's projected expenses for 2026 are expected to reach $105 billion, which is over 4% higher than Wall Street's expectations, raising concerns among investors [3][5]. - The current stock price of JPMorgan is $300.47, reflecting a decrease of 4.68%, with a change of -$14.74 [3]. Stock Resilience - Despite the recent decline, JPMorgan's stock has shown resilience over the past year, with a high of $322.25 and a low of $202.16 [4][5]. - The company's market capitalization is approximately $817.96 billion, indicating its strong position in the financial sector [4][5]. - Today's trading volume for JPMorgan is 15,022,965 shares on the NYSE, highlighting active investor interest [4].

Group 1 - Benitec Biopharma Limited (BNTC) closed at $13.18, with a 9.8% gain over the past four weeks, and a mean price target of $24.71 suggests an 87.5% upside potential [1] - The mean estimate includes seven short-term price targets with a standard deviation of $6.07, indicating variability among analysts; the lowest estimate is $17.00 (29% increase), while the highest is $32.00 (142.8% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 52.3%, with four estimates moving higher and no negative revisions in the last 30 days [12] - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Jade Biosciences, Inc. (JBIO) shares have increased by 25% in the last four weeks, closing at $12, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $19.8, representing a 65% upside [1][11]. Price Targets and Analyst Consensus - The average price target for JBIO ranges from a low of $16.00 to a high of $28.00, with a standard deviation of $4.76, indicating a potential increase of 33.3% to 133.3% from the current price [2][11]. - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9][10]. Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about JBIO's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 14.2% over the past month, with two estimates increasing and no negative revisions [12][13]. Zacks Rank and Investment Potential - JBIO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside in the near term [13][14].

Core Viewpoint - UBS has raised its price target on Macy's to $7.00 from $6.50 while maintaining a Sell rating [1] Group 1: Earnings Forecast - UBS's recent channel checks indicated stronger-than-expected third-quarter sales trends, prompting an increase in Q3 earnings forecast by $0.18 to a loss of $0.12 per share, with an expectation of an EPS beat of $0.03 [2] - Despite the improved quarterly outlook, Macy's is likely to reaffirm its fiscal 2025 guidance due to ongoing uncertainties related to tariffs and macroeconomic conditions [2] Group 2: Market Expectations - The market seems to anticipate a similar stance from Macy's management, which reduces the likelihood of significant revisions to consensus estimates or major movements in the stock's valuation multiple following the earnings report [3] - There is potential upside if Macy's provides more positive commentary on early fourth-quarter trends, but elevated bullish sentiment could turn the Q3 release into a "market-clearing event" [3] - The options market is pricing in a ±10.5% move on earnings, which is higher than Macy's historical average of 7.8%, indicating expectations for increased post-print volatility [3]

Core Viewpoint - Evercore ISI has lowered its price target for Alexandria Real Estate Equities to $72 from $74 while maintaining an Outperform rating, indicating a cautious but positive outlook ahead of the company's annual investor day on December 3 [1] Group 1: Company Performance - Alexandria Real Estate Equities has faced weak fundamentals in the lab space, strained capital markets for life sciences and biotech firms, and deteriorating portfolio metrics, leading to a nearly 50% decline in shares year-to-date, which has pushed the dividend yield to approximately 10% [2] - The firm has slightly reduced its 2026 FFO forecast to $6.52 from $6.55 and its 2027 estimate to $7.05 from $7.36, primarily due to lower starting cash rents and higher operating costs [3] Group 2: Market Positioning - Despite the lowered estimates, Evercore maintains an Outperform rating, citing low expectations ahead of the investor day and an attractive valuation, with the stock trading at just 9.5 times its new 2027 AFFO estimate compared to a REIT sector average of 19.6 times [3]